MESO catalysts
Catalysts and events linked to MESO, newest first.
MESO stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch 2026-08-27 · Up | commercial cash flow transition and Phase 3 trial completion | Full-year revenue reached $120.3M with $115.2M generated by RYONCIL and Phase 3 low back pain dosing completed. | Not recorded |
| Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch 2026-08-27 · Up | commercial product revenue ramp accelerating operational cash flow | Total FY2026 revenue of $120.3M with $115.2M from RYONCIL net sales | Not recorded |
| Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial 2026-08-27 · Up | commercial cash flow expansion and clinical milestone completion | Reported $120.3M revenue with $115.2M from RYONCIL and completed Phase 3 treatment. | Not recorded |
Do these developments change your position?
Review MESO alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain TrialMESO
- 2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain TrialMESO
- 2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain TrialMESO
- 2026-08-27Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial LaunchMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for Ryoncil → Bullish MESO → Bullish MESOMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for Ryoncil → Bullish MESOMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for RyoncilMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for RyoncilMESO
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.